SignalFDA/Bio

Bayer won U.S. FDA approval for a first-in-class stroke blood thinner

FDA approval of a first-in-class stroke blood thinner is a major biotech catalyst.

Context

What happened: The FDA approved Bayer's Sunharbo, a once-daily pill, to reduce the risk of another stroke. Key numbers: The trial showed a 26% reduction in ischemic stroke. Why it matters: The approval covers a first-in-class blood thinner, giving Bayer a new product in the stroke prevention market.

What changed

The FDA approved Bayer's Sunharbo, a once-daily pill, to reduce the risk of another stroke.

Why it matters

The approval covers a first-in-class blood thinner, giving Bayer a new product in the stroke prevention market.

Sources